These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 37885829)

  • 1. "TO BE OR NOT TO BE" GWAS Ends the Controversy about the DRD2 Gene as a Determinant of Reward Deficiency Syndrome (RDS).
    Blum K; Thanos PK; Hanna C; Gold MS; Baron D; Elman I
    Psychol Res Behav Manag; 2023; 16():4287-4291. PubMed ID: 37885829
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence for the
    Blum K; Bowirrat A; Elman I; Baron D; Thanos PK; Gold MS; Hanna C; Makale MT; Sunder K; Jafari N; Zeine F; Murphy KT; Makale M; Badgaiyan RD
    Clin Exp Psychol; 2023 Jun; 9(4):8-11. PubMed ID: 37560184
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Do dopaminergic gene polymorphisms affect mesolimbic reward activation of music listening response? Therapeutic impact on Reward Deficiency Syndrome (RDS).
    Blum K; Chen TJ; Chen AL; Madigan M; Downs BW; Waite RL; Braverman ER; Kerner M; Bowirrat A; Giordano J; Henshaw H; Gold MS
    Med Hypotheses; 2010 Mar; 74(3):513-20. PubMed ID: 19914781
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Statistical Validation of Risk Alleles in Genetic Addiction Risk Severity (GARS) Test: Early Identification of Risk for Alcohol Use Disorder (AUD) in 74,566 Case-Control Subjects.
    Blum K; Han D; Gupta A; Baron D; Braverman ER; Dennen CA; Kazmi S; Llanos-Gomez L; Badgaiyan RD; Elman I; Thanos PK; Downs BW; Bagchi D; Gondre-Lewis MC; Gold MS; Bowirrat A
    J Pers Med; 2022 Aug; 12(9):. PubMed ID: 36143170
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic Addiction Risk and Psychological Profiling Analyses for "Preaddiction" Severity Index.
    Blum K; Han D; Bowirrat A; Downs BW; Bagchi D; Thanos PK; Baron D; Braverman ER; Dennen CA; Gupta A; Elman I; Badgaiyan RD; Llanos-Gomez L; Khalsa J; Barh D; McLaughlin T; Gold MS
    J Pers Med; 2022 Oct; 12(11):. PubMed ID: 36579510
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In Search of Reward Deficiency Syndrome (RDS)-free Controls: The "Holy Grail" in Genetic Addiction Risk Testing.
    Blum K; Baron D; Lott L; Ponce JV; Siwicki D; Boyett B; Steinberg B; Modestino EJ; Fried L; Hauser M; Simpatico T; Downs BW; McLaughlin T; Hajela R; Badgaiyan RD
    Curr Psychopharmacol; 2020; 9(1):7-21. PubMed ID: 32432025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of the Association of D2 Dopamine Receptor Gene and Reported Allele Frequencies With Alcohol Use Disorders: A Systematic Review and Meta-analysis.
    Jung Y; Montel RA; Shen PH; Mash DC; Goldman D
    JAMA Netw Open; 2019 Nov; 2(11):e1914940. PubMed ID: 31702801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute intravenous synaptamine complex variant KB220™ "normalizes" neurological dysregulation in patients during protracted abstinence from alcohol and opiates as observed using quantitative electroencephalographic and genetic analysis for reward polymorphisms: part 1, pilot study with 2 case reports.
    Miller DK; Bowirrat A; Manka M; Miller M; Stokes S; Manka D; Allen C; Gant C; Downs BW; Smolen A; Stevens E; Yeldandi S; Blum K
    Postgrad Med; 2010 Nov; 122(6):188-213. PubMed ID: 21084795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased prevalence of the Taq I A1 allele of the dopamine receptor gene (DRD2) in obesity with comorbid substance use disorder: a preliminary report.
    Blum K; Braverman ER; Wood RC; Gill J; Li C; Chen TJ; Taub M; Montgomery AR; Sheridan PJ; Cull JG
    Pharmacogenetics; 1996 Aug; 6(4):297-305. PubMed ID: 8873216
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biotechnical development of genetic addiction risk score (GARS) and selective evidence for inclusion of polymorphic allelic risk in substance use disorder (SUD).
    Blum K; Bowirrat A; Baron D; Lott L; Ponce JV; Brewer R; Siwicki D; Boyett B; Gondre-Lewis MC; Smith DE; Panayotis K T; Badgaiyan S; Hauser M; Fried L; A R; Downs BW; Badgaiyan RD
    J Syst Integr Neurosci; 2020 Aug; 6(2):. PubMed ID: 33614164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Benefits of Genetic Addiction Risk Score (GARS
    Blum K; Modestino EJ; Gondre-Lewis M; Chapman EJ; Neary J; Siwicki D; Baron D; Hauser M; Smith DE; Roy AK; Thanos PK; Steinberg B; McLaughlin T; Fried L; Barh D; Dunston GA; Badgaiyan RD
    Int J Genom Data Min; 2018; 2018(1):. PubMed ID: 30198022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Theorizing the Role of Dopaminergic Polymorphic Risk Alleles with Intermittent Explosive Disorder (IED), Violent/Aggressive Behavior and Addiction: Justification of Genetic Addiction Risk Severity (GARS) Testing.
    Modestino EJ; Blum K; Dennen CA; Downs BW; Bagchi D; Llanos-Gomez L; Elman I; Baron D; Thanos PK; Badgaiyan RD; Braverman ER; Gupta A; Gold MS; Bowirrat A
    J Pers Med; 2022 Nov; 12(12):. PubMed ID: 36556167
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Should Reward Deficiency Syndrome (RDS) Be Considered an Umbrella Disorder for Mental Illness and Associated Genetic and Epigenetic Induced Dysregulation of Brain Reward Circuitry?
    Blum K; Dennen CA; Elman I; Bowirrat A; Thanos PK; Badgaiyan RD; Downs BW; Bagchi D; Baron D; Braverman ER; Gupta A; Green R; McLaughlin T; Barh D; Gold MS
    J Pers Med; 2022 Oct; 12(10):. PubMed ID: 36294858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Coupling Neurogenetics (GARS™) and a Nutrigenomic Based Dopaminergic Agonist to Treat Reward Deficiency Syndrome (RDS): Targeting Polymorphic Reward Genes for Carbohydrate Addiction Algorithms.
    Blum K; Simpatico T; Badgaiyan RD; Demetrovics Z; Fratantonio J; Agan G; Febo M; Gold MS
    J Reward Defic Syndr; 2015; 1(2):75-80. PubMed ID: 27617300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypothesizing dopaminergic genetic antecedents in schizophrenia and substance seeking behavior.
    Blum K; Oscar-Berman M; Badgaiyan RD; Palomo T; Gold MS
    Med Hypotheses; 2014 May; 82(5):606-14. PubMed ID: 24636783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The taqI DRD2 A1 allele is associated with alcohol-dependence although its effect size is small.
    Berggren U; Fahlke C; Aronsson E; Karanti A; Eriksson M; Blennow K; Thelle D; Zetterberg H; Balldin J
    Alcohol Alcohol; 2006; 41(5):479-85. PubMed ID: 16751215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic Addiction Risk Severity Assessment Identifies Polymorphic Reward Genes as Antecedents to Reward Deficiency Syndrome (RDS) Hypodopaminergia's Effect on Addictive and Non-Addictive Behaviors in a Nuclear Family.
    Dennen CA; Blum K; Bowirrat A; Thanos PK; Elman I; Ceccanti M; Badgaiyan RD; McLaughlin T; Gupta A; Bajaj A; Baron D; Downs BW; Bagchi D; Gold MS
    J Pers Med; 2022 Nov; 12(11):. PubMed ID: 36579592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Associations of the DRD2 TaqIA polymorphism with impulsivity and substance use: preliminary results from a clinical sample of adolescents.
    Esposito-Smythers C; Spirito A; Rizzo C; McGeary JE; Knopik VS
    Pharmacol Biochem Behav; 2009 Sep; 93(3):306-12. PubMed ID: 19344737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic Addiction Risk Score (GARS): molecular neurogenetic evidence for predisposition to Reward Deficiency Syndrome (RDS).
    Blum K; Oscar-Berman M; Demetrovics Z; Barh D; Gold MS
    Mol Neurobiol; 2014 Dec; 50(3):765-96. PubMed ID: 24878765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polymorphisms of the D2 dopamine receptor gene and alcoholism and other substance use disorders.
    Noble EP
    Alcohol Alcohol Suppl; 1994; 2():35-43. PubMed ID: 8974314
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.